Alaunos Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Alaunos Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00.
- Alaunos Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00.
- Alaunos Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $998.00K.
- Alaunos Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $0.00.
- Alaunos Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $998.00K.
- Alaunos Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $92.00K, a 99.38% decline from fiscal 2022.
- Alaunos Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $14.72M.
- Alaunos Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $13.02M, a 113.90% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $998.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | |
| 2025-06-30 | $998.00K 10-Q · filed 2026-08-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $92.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | |
| 2023-03-31 | $92.00K 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $14.72M 10-K · filed 2024-04-01 | |
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $13.02M 10-K · filed 2022-03-30 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $16.13M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $19.10M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $13.02M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $6.08M 10-K · filed 2021-03-01 |
| 2019-09-30 | $2.97M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $47.10M 10-K · filed 2020-03-02 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $47.27M 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $94.32M 10-K · filed 2018-03-01 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | |
| 2015-03-31 | $94.32M 10-Q · filed 2015-05-07 | |
| 2013-12-31 | $53.88M 10-K · filed 2016-02-24 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-08 | |
| 2012-06-30 | $1.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-08-28 | |
| 2012-03-31 | $49.17M 10-Q · filed 2012-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |